FindTrial
Sign In

Registry of anti-cancer treatment response prediction tool, CANscript, to understand its use in clinics and impact on the patient treatment outcome.

A Multicenter Registry Examining the Clinical Utility of CANscript in Routine Clinical Practice. - PREDiCTS-India Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/12/016813
Enrollment
2000
Registered
2018-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Solid cancer

Interventions

None listed

Sponsors

Mitra RxDx India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient who has been recommended to undergo CANscript testing, as a part of routine clinical practice, by the treating physician. Patient for whom the CANscript test report (at least 1 reported M-score) is available for review Patient willing to provide informed consent for prospective data collection

Exclusion criteria

Exclusion criteria: No specific exclusion criteria can be defined for the registry enrollment.

Design outcomes

Secondary

MeasureTime frame
To investigate the treatment outcomes in the cancer patients.Timepoint: 12 months—

Primary

MeasureTime frame
To collect data on CANscript test focusing on routine clinical utilization and treatment decision impact in the management of cancer patients.Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Rahul Rathod

Mitra RxDx India Pvt. Ltd. Bengaluru

rahul.rathod@mitrabiotech.com080-61318890

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026